dc.contributor.author |
Ghanem, Georges |
|
dc.contributor.author |
Hammoudeh, Ayman J. |
|
dc.contributor.author |
Echtay, Akram |
|
dc.contributor.author |
Haddad, Jihad |
|
dc.date.accessioned |
2016-06-15T07:35:10Z |
|
dc.date.available |
2016-06-15T07:35:10Z |
|
dc.date.copyright |
2014 |
en_US |
dc.date.issued |
2016-06-15 |
|
dc.identifier.issn |
0300-7995 |
en_US |
dc.identifier.uri |
http://hdl.handle.net/10725/4038 |
|
dc.description.abstract |
Background:
Jump to section
Background:
Design and methods:
Results:
Conclusions:
Introduction
Methods
Results
Discussion
Conclusions
Transparency
Several studies that evaluated achieving lipid goals have demonstrated an undertreatment of dyslipidemia. We evaluated the use and efficacy of lipid-lowering agents (LLAs) in reducing low-density lipoprotein cholesterol (LDL-C) to recommended levels in the Levant region.
Design and methods:
Jump to section
Background:
Design and methods:
Results:
Conclusions:
Introduction
Methods
Results
Discussion
Conclusions
Transparency
A multi-center, cross-sectional survey enrolled 1002 dyslipidemic patients (August 2010 – January 2011) on LLAs for ≥3 months. Collection of data and blood samples was done over one visit. Physicians and patients filled out questionnaires pertaining to dyslipidemia diagnosis and treatment. LDL-C target levels were defined according to international guidelines.
Results:
Jump to section
Background:
Design and methods:
Results:
Conclusions:
Introduction
Methods
Results
Discussion
Conclusions
Transparency
The full analysis set included 992 patients. Mean age was 58.0 ± 11.6 years (41% women, 65.7% diabetics and 51.5% had history of coronary heart disease). LLAs were prescribed for primary prevention or secondary prevention or familial hypercholesterolemia in 45.8% and 52.8% and 1.4% of patients; respectively. Overall, 64.0% and 56.8% of the patients attained their LDL-C goal recommended by the NCEP ATP III and TJETF guidelines, respectively. According to the 2004 NCEP ATP III updated guidelines, about 24.8% of the very high risk group attained their LDL goal of ≤70 mg/dL. Smoking, diabetes, metabolic syndrome, history of cardiovascular disease, increased waist circumference, and elevated pre-treatment LDL-C level were all associated with not reaching LDL-C goals.
Conclusions:
Jump to section
Background:
Design and methods:
Results:
Conclusions:
Introduction
Methods
Results
Discussion
Conclusions
Transparency
Although the study cohort was a relatively high risk group and might not be representative of the general population, we found that about 60% of enrolled individuals achieved the LDL-C treatment goals and 24.8% of the very high risk group achieved the recommended LDL-C targets of ≤70 mg/dl; national strategies and aggressive awareness campaigns to effectively control lipid levels to recommended target levels, especially in the high risk groups, are urgently needed. |
en_US |
dc.language.iso |
en |
en_US |
dc.title |
Achieving low-density lipoprotein cholesterol treatment goals among dyslipidemic individuals in the Levant |
en_US |
dc.type |
Article |
en_US |
dc.description.version |
Published |
en_US |
dc.title.subtitle |
the CEntralized Pan-Levant survey on tHE Undertreatment of hypercholeSterolemia (CEPHEUS) study |
en_US |
dc.author.school |
SOM |
en_US |
dc.author.idnumber |
201000163 |
en_US |
dc.author.department |
N/A |
en_US |
dc.description.embargo |
N/A |
en_US |
dc.relation.journal |
Current Medical Research and Opinion |
en_US |
dc.journal.volume |
30 |
en_US |
dc.journal.issue |
10 |
en_US |
dc.article.pages |
1957-1965 |
en_US |
dc.keywords |
Cardiovascular diseases |
en_US |
dc.keywords |
Low-density lipoprotein cholesterol |
en_US |
dc.keywords |
Statins |
en_US |
dc.keywords |
Treatment goals |
en_US |
dc.identifier.doi |
http://dx.doi.org/ 10.1007/BF0012365710.1185/03007995.2014.929095 |
en_US |
dc.identifier.ctation |
Hammoudeh, A. J., Echtay, A., Ghanem, G. Y., & Haddad, J. (2014). Achieving low-density lipoprotein cholesterol treatment goals among dyslipidemic individuals in the Levant: the CEntralized Pan-Levant survey on tHE Undertreatment of hypercholeSterolemia (CEPHEUS) study. Current medical research and opinion, 30(10), 1957-1965. |
en_US |
dc.author.email |
george.ghanem@lau.edu.lb |
en_US |
dc.identifier.tou |
http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.php |
en_US |
dc.identifier.url |
http://www.tandfonline.com/doi/abs/10.1185/03007995.2014.929095 |
en_US |